Angiotensin receptors in GtoPdb v.2023.1

Authors

  • Wayne Alexander Emory University
  • Kenneth E. Bernstein Cedars-Sinai Medical Center
  • Kevin J. Catt National Institutes of Health
  • Marc de Gasparo Novartis Institutes for Biomedical Research
  • Khuraijam Dhanachandra Singh Cleveland Clinic Lerner Research Institute https://orcid.org/0000-0003-0506-6896
  • Satoru Eguchi Temple University
  • Emanuel Escher Universite de Sherbrooke https://orcid.org/0000-0001-6601-987X
  • Theodore L. Goodfriend Veterans Administration Hospital Wisconsin
  • Mastgugu Horiuchi Ehime University
  • László Hunyady Semmelweis University
  • Ahsan Husain University of Alabama at Birmingham
  • Tadashi Inagami Vanderbilt University
  • Sadashiva Karnik Cleveland Clinic Lerner Research Institute
  • Jacqueline Kemp Cleveland Clinic Lerner Research Institute
  • Walter G. Thomas University of Queensland
  • Pieter B. M. W. M. Timmermans Tularik
  • Kalyan Tirupula Cleveland Clinic Lerner Research Institute
  • Hamiyet Unal Cleveland Clinic Lerner Research Institute
  • Thomas Unger Christian-Albrechts-Universität zu Kiel
  • Patrick Vanderheyden Vrije Universiteit Brussel

DOI:

https://doi.org/10.2218/gtopdb/F6/2023.1

Abstract

The actions of angiotensin II (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors [63, 155]), which have around 30% sequence similarity. The decapeptide angiotensin I, the octapeptide angiotensin II and the heptapeptide angiotensin III are endogenous ligands. losartan, candesartan, olmesartan, telmisartan, etc. are clinically used AT1 receptor blockers.

Downloads

Published

26-Apr-2023

How to Cite

Alexander, W. (2023) “Angiotensin receptors in GtoPdb v.2023.1”, IUPHAR/BPS Guide to Pharmacology CITE, 2023(1). doi: 10.2218/gtopdb/F6/2023.1.

Issue

Vol. 2023 No. 1 (2023)

Section

Summaries